As of November 10, 2026, Heron Therapeutics, Inc. is a publicly traded company (Nasdaq: HRTX). The largest holder reporting an active stake on Schedule 13D is Rubric Capital Management LP, at 15.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Clearline Capital LP (6.7%) (Schedule 13D/A, October 17, 2025).
Is this your company?
About to sign with, pay or invest in Heron Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Heron Therapeutics, Inc. a real, registered company?
- Heron Therapeutics, Inc. files with the SEC under CIK 818033 (its SEC filings).
- Its shares are listed under the ticker HRTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under HERON THERAPEUTICS, INC. /DE/ in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Clearline Capital LP (filed 2026-02-17).
Who are Heron Therapeutics, Inc.'s owners and officers?
Heron Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-05-13).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2023-08-01)
- : Director (Form D, 2023-08-01)
- : Director (Form D, 2023-08-01)
- : Director (Form D, 2023-08-01)
- : Director (Form D, 2023-08-01)
- : Executive Officer, Director (Form D, 2023-08-01)
- : Director (Form D, 2023-08-01)
- : Executive Officer (Form D, 2023-08-01)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 0% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Clearline Capital LP | 6.7% |
| Schedule 13G, 2026-01-30 | The Vanguard Group | 5.35% |
| Schedule 13G, 2025-11-26 | Clearline Capital LP | 5.3% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 4.61% |
| Schedule 13D/A, 2025-10-17 | Rubric Capital Management LP | 15.9% |
| Schedule 13D/A, 2025-08-12 | Rubric Capital Management LP | 17.5% |
Questions about who owns Heron Therapeutics, Inc.
Who owns Heron Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Heron Therapeutics, Inc.: Rubric Capital Management LP (15.9%, Schedule 13D/A, filed 2025-10-17) and Clearline Capital LP (6.7%, Schedule 13G/A, filed 2026-02-17).
Who are the largest shareholders of Heron Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Heron Therapeutics, Inc. on this page are Rubric Capital Management LP (15.9%) and Clearline Capital LP (6.7%).
When did Rubric Capital Management LP buy into Heron Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rubric Capital Management LP on this page is the Schedule 13D/A, filed 2025-08-12, reporting 17.5%; its latest, Schedule 13D/A filed 2025-10-17, reports 15.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Heron Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Heron Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Heron Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Heron Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 30,046,828 shares (15.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-17).
- Rubric Capital Management LP, a 10% owner: 30,046,828 shares (15.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-17).
- , a director: 8,877,027 shares (4.7% of shares outstanding), 123,737 held directly and 8,753,290 indirectly (Form 4, 2026-02-03).
- , the chief executive and a director: 931,086 shares (0.49% of shares outstanding) (Form 4, 2026-11-03).
- , the chief financial officer and executive vice president: 302,724 shares (0.16% of shares outstanding) (Form 4, 2026-11-03).
Shares outstanding: 190,273,587 as of 2026-11-04, from the company's latest SEC cover page.
How much has Heron Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-08-01 | $30M | $30M |
Keep reading
More on Heron Therapeutics, Inc. and the records around it.
Heron Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- Clearline Capital LP also filed stake reports on 2 other companies: Xperi Inc. (Aug 2026), MAGNACHIP SEMICONDUCTOR Corp (Feb 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/heron-therapeutics